Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Clinical considerations for the management of residual diabetes following bariatric surgery.
Kashyap SR, Schauer P.
Diabetes Obes Metab. 2012 Jan 30. doi: 10.1111/j.1463-1326.2012.01577.x. [Epub ahead of print]
Related citations
Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis.
Dunkley AJ, Charles K, Gray LJ, Camosso-Stefinovic J, Davies MJ, Khunti K.
Diabetes Obes Metab. 2012 Jul;14(7):616-25. doi: 10.1111/j.1463-1326.2012.01571.x. Epub 2012 Feb 21.
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
Luippold G, Klein T, Mark M, Grempler R.
Diabetes Obes Metab. 2012 Jul;14(7):601-7. doi: 10.1111/j.1463-1326.2012.01569.x. Epub 2012 Feb 23.
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R.
Diabetes Obes Metab. 2012 Jul;14(7):666-9. doi: 10.1111/j.1463-1326.2012.01566.x. Epub 2012 Feb 13.
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M.
Diabetes Obes Metab. 2012 May;14(5):470-8. doi: 10.1111/j.1463-1326.2012.01565.x. Epub 2012 Feb 16.
Acute high-intensity interval exercise reduces the postprandial glucose response and prevalence of hyperglycaemia in patients with type 2 diabetes.
Gillen JB, Little JP, Punthakee Z, Tarnopolsky MA, Riddell MC, Gibala MJ.
Diabetes Obes Metab. 2012 Jun;14(6):575-7. doi: 10.1111/j.1463-1326.2012.01564.x. Epub 2012 Feb 20.
The timing of dialysis and kidney transplantation in type 1 diabetes.
Pavlakis M.
Diabetes Obes Metab. 2012 Jan 12. doi: 10.1111/j.1463-1326.2012.01562.x. [Epub ahead of print]
Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial.
van Dieren S, Czernichow S, Chalmers J, Kengne AP, de Galan BE, Poulter N, Woodward M, Beulens JW, Grobbee DE, van der Schouw YT, Zoungas S.
Diabetes Obes Metab. 2012 May;14(5):464-9. doi: 10.1111/j.1463-1326.2012.01556.x. Epub 2012 Feb 8.
Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
van der Zijl NJ, Moors CC, Goossens GH, Blaak EE, Diamant M.
Diabetes Obes Metab. 2012 Jul;14(7):586-95. doi: 10.1111/j.1463-1326.2012.01559.x. Epub 2012 Feb 13.
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S.
Diabetes Obes Metab. 2012 Jun;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x. Epub 2012 Feb 8.
Treating diabetes today with gliclazide MR: a matter of numbers.
Avogaro A.
Diabetes Obes Metab. 2012 Jan;14 Suppl 1:14-9. doi: 10.1111/j.1463-1326.2011.01508.x. Review.
Treating diabetes today: a matter of selectivity of sulphonylureas.
Seino S, Takahashi H, Takahashi T, Shibasaki T.
Diabetes Obes Metab. 2012 Jan;14 Suppl 1:9-13. doi: 10.1111/j.1463-1326.2011.01507.x. Review.
Optimal management of type 2 diabetes: the evidence.
Colagiuri S.
Diabetes Obes Metab. 2012 Jan;14 Suppl 1:3-8. doi: 10.1111/j.1463-1326.2011.01506.x. Review.
What matters in ADVANCE and ADVANCE-ON.
Hamet P.
Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x. Review.
Wisdom-based and evidence-based medicine.
Matthews DR.
Diabetes Obes Metab. 2012 Jan;14 Suppl 1:1-2. doi: 10.1111/j.1463-1326.2011.01514.x. No abstract available.
Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.
Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ.
Diabetes Obes Metab. 2012 May;14(5):424-32. doi: 10.1111/j.1463-1326.2011.01552.x. Epub 2012 Jan 17.
Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how?
Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC.
Diabetes Obes Metab. 2012 Jul;14(7):579-585. doi: 10.1111/j.1463-1326.2011.01551.x. Epub 2012 Jan 17.
The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A.
Diabetes Obes Metab. 2012 Jun;14(6):518-22. doi: 10.1111/j.1463-1326.2011.01550.x. Epub 2012 Jan 6.
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.
Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.
Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
Gonçalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, Reis F, Ambrósio AF, Fernandes R.
Diabetes Obes Metab. 2012 May;14(5):454-63. doi: 10.1111/j.1463-1326.2011.01548.x. Epub 2012 Jan 6.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on